DBV Technologies SA Sponsored ADR DBVT 深 滬
等待開盤 02-04 09:30:00 美东时间
22.50
+0.910
+4.21%
華盛通- 最 高22.89
- 今 開21.93
- 成交量 60.85万股
- 最 低 21.79
- 昨 收 21.59
- 總市值 6.16亿
- 52周最高 26.185
- 市盈率 靜 --
- 換手率 2.22%
- 52周最低 3.82
- 委 比 94.81%
- 總股本 2737.25万
- 歷史最高 505.70
- 量 比 1.69
- 振 幅 5.09%
- 歷史最低 3.15
- 每 手 1
- 風險率 4.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on ...
01-16 22:55
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies, a clinical-stage biopharmaceutical company, has issued a Half-Year Report on its liquidity contract with ODDO BHF as of December 31, 2025. The liquidity account included 74,580 DBV shares and €527,891.63. Since the contract's implementation in July 2018, the account initially held 41,159 shares and €432,367.25. From July 1 to December 31, 2025, there were 1,658 buy transactions and 1,867 sales transactions, involving 1,496,975 s...
01-07 21:00
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
2025-12-31 23:01
美股牛股 | Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%
Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%，与Coursera合并以扩大全球AI教育市场份额>>
2025-12-18 19:07
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
欧洲股市受科技股拖累抹去盘中涨幅 富时100指数上涨
欧洲股市回吐盘中涨幅，投资者对人工智能的担忧再起，令科技股承压下跌。在数据显示通胀降幅大于预期后，英国富时100指数表现领先。 斯托克欧洲600指数收盘...
2025-12-18 02:32
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
2025-12-18 01:06
盘前：纳指期货涨0.44% 特朗普将发表全国讲话
在最新公布的美国就业数据未能进一步强化美联储继续降息理由的背景下，周三美国国债和美股期指小幅波动，美元走强。与此同时，美国总统特朗普加大对委内瑞拉的施压力度...
2025-12-17 21:30
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Cantor Fitzgerald Initiates Coverage On DBV Technologies with Overweight Rating, Announces Price Target of $42
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on DBV Technologies (NASDAQ:DBVT) with a Overweight rating and announces Price Target of $42.
2025-12-15 19:33
